362604-25-9

Upstream product

• 335293-17-9 6-carbomethoxy-7-chloro-4-hydroxy-3-(3,4,5-trimethylphenyl)-1H-quinolin-2-one 
• 2916-68-9 2-(Trimethylsilyl)ethanol 
• 362604-23-7 7-chloro-3-(3,4,5-trimethyl-phenyl)-2,4-bis-(2-trimethylsilanyl-ethoxy)-quinoline-6-carboxylic acid methyl ester 

Downstream Products

• 808172-48-7 7-Chloro-4-[2-((R)-4-oxo-azetidin-2-yl)-ethoxy]-3-(3,4,5-trimethyl-phenyl)-2-(2-trimethylsilanyl-ethoxy)-quinoline-6-carboxylic acid [1,2,5]thiadiazol-3-ylamide 
• 808172-45-4 7-chloro-4-hydroxy-3-(3,4,5-trimethyl-phenyl)-2-(2-trimethylsilanyl-ethoxy)-quinoline-6-carboxylic acid [1,2,5]thiadiazol-3-ylamide 
• 362604-27-1 7-chloro-3-(3,4,5-trimethyl-phenyl)-2,4-bis-(2-trimethylsilanyl-ethoxy)-quinoline-6-carboxylic acid [1,2,5]thiadiazol-3-ylamide 

Relevant academic research and scientific papers

Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists

Potent neutral replacements of the basic amine at the 4-position of quinolone non-peptide GnRH antagonists are reported. A series of neutral, nonbasic quinolone GnRH antagonists were prepared via Mitsunobu alkylation of protected and unprotected 4-hydroxy quinolone intermediates. The synthetic route was improved by utilization of unique reactivity and convergency afforded by the use of mono and bis-trimethylsilylethyl protected quinolones. Potent neutral GnRH antagonists were identified, including ether and lactam derivatives, that show similar in vitro binding affinity and functional activity as compared to the earlier basic 4-aminoalkyl quinolone series of nonpeptide GnRH antagonists.